StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Up 12.0 %

EGRX stock opened at $1.40 on Friday. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.37. The firm’s 50 day moving average price is $1.03 and its 200-day moving average price is $1.35.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several large investors have recently modified their holdings of the business. RBF Capital LLC increased its position in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Eagle Pharmaceuticals during the third quarter worth about $453,000. DGS Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after acquiring an additional 22,239 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Eagle Pharmaceuticals in the 3rd quarter valued at approximately $96,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.